Kairos Pharma, Ltd. (KAPA) is a Los Angeles-based, clinical-stage oncology company developing antibody and small-molecule therapies designed to overcome drug resistance and immune suppression in cancer. Its lead asset, ENV-105 (carotuximab), targets CD105 and is in Phase 2 testing in metastatic castration-resistant prostate cancer and Phase 1 testing in EGFR-driven non-small cell lung cancer. Shares closed Monday at $0.4069, down $0.0467, or 10.30%, from the prior close of $0.4536 — a confirmed move to the downside and a new 52-week low. The immediate reason cited by the market was the previous Friday's quarterly filing, which carried going-concern language and a wider loss, with Monday offering the first full session to react to it.
The quarterly report filed after Friday's close stated that recurring losses since inception and $3.03 million of cash used in operations during the first nine months of 2026 raise substantial doubt about the company's ability to continue as a going concern. Cash and equivalents stood at $3.125 million at September 30, down from $4.491 million at the end of 2025, while the nine-month net loss widened to $5.03 million, or $1.60 per share, from $4.08 million a year earlier. Third-quarter red ink alone reached $1.98 million. Management said existing cash may not fund planned operations for the next 12 months and pointed to equity offerings, debt, collaborations, or licensing as funding routes.
For a company with a market value of roughly $1.9 million, that language is material rather than cosmetic. It reframes the investment case around survival financing instead of clinical milestones, and it explains why the stock gave back ground on the first trading day after the disclosure became public.
The filing also refreshed details on the company's funding machinery. Kairos raised $1.87 million gross through its at-the-market program during the first nine months of the year, sold 752,947 shares, and raised another $1.558 million after quarter-end. It separately extended its equity line of credit with Helena Global Investment Opportunities through December 31, 2028 and shortened the pricing period to a single trading day, a structure that can accelerate share issuance at depressed prices. Shares outstanding reached 4,685,025 by November 13, up roughly 52% year over year, and the company completed a 1-for-7 reverse split effective September 1.
Against that backdrop, each rebound has met fresh supply. The stock is down about 74% since October 5 and about 94% below its 52-week high of $7.28, a pattern consistent with sustained dilution into a shrinking equity base rather than a single piece of bad news.
Monday's tape was unhelpful. The small-cap biotech benchmark fell roughly 3.1% and the large-cap biotech gauge about 2.1%, so part of the decline was sector-wide risk reduction. KAPA nonetheless more than tripled the sector's loss, indicating that company-specific concerns about financing did most of the work. Volume of about 12,700 shares was only around 3.5% of the three-month average, a reminder that at this size a modest flow of sell orders can move the tape several percentage points. Technically, the close near $0.4069 broke below the November 3 low and sits well beneath any short-term moving average, leaving little visible support except round-number levels near $0.40 and $0.35.
On this scale, 0 describes a session with no meaningful verified news and a price move that is ordinary for the stock, while 100 describes transformative news paired with an extreme, rare move. The score here is 31 out of 100. The verified news is moderate but genuine: a quarterly report that widened the nine-month loss to $5.03 million and repeated substantial-doubt language about going concern at a company with no revenue and a market value near $2 million. The move itself was only about twice the stock's typical daily swing of roughly 5.3%, and declines of similar or larger size occurred in about eight of the prior 60 sessions. A real but not transformative catalyst is therefore paired with a fairly routine move.
Attention now shifts to financing. Traders will look for an announcement of new capital, a revamped ATM program, or a partnership that extends the cash runway, since any of these could reset the dilution math in either direction. On the clinical side, the company has said its ENV-105 prostate cancer program will focus on first-line therapy after enzalutamide in a larger patient group, while the lung cancer Phase 1 remains under way; updates from either could move the stock sharply given the small float. The next scheduled financial update is the fourth-quarter and full-year 2026 report, which has not yet been dated. Two analysts cover the name with a consensus rating of Buy, though ratings have lagged a share price that has fallen more than 90% in a year. Key risks include failed or delayed trials, further equity issuance at low prices, potential continued-listing issues tied to a sub-$1 share price, and the possibility that financing arrives on unfavorable terms.
Tickeron operates hundreds of AI trading bots covering thousands of tickers, and only the strongest performers under current market conditions are surfaced in its curated Trending AI Robots section. The bots differ widely by strategy, timeframe, performance metrics, and the symbols they trade, so the lineup changes as market conditions shift. Volatile, low-priced names like this one are precisely where automated strategies can add discipline to entry and exit decisions. Reviewing the current leaders is a practical next step for traders refining their approach.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Be on the lookout for a price bounce soon.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where KAPA's RSI Oscillator exited the oversold zone, 19 of 22 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 86%.
The Moving Average Convergence Divergence (MACD) for KAPA just turned positive on October 28, 2026. Looking at past instances where KAPA's MACD turned positive, the stock continued to rise in 17 of 22 cases over the following month. The odds of a continued upward trend are 77%.
Following a +11.09% 3-day Advance, the price is estimated to grow further. Considering data from situations where KAPA advanced for three days, in 78 of 95 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
KAPA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where KAPA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for KAPA entered a downward trend on November 18, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.394) is normal, around the industry mean (3.592). P/E Ratio (-0.249) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (442.120).
The Tickeron PE Growth Rating for this company is 91 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 95 (best 1 - 100 worst), indicating slightly worse than average price growth. KAPA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. KAPA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry Biotechnology